Counseling patients and the management of adverse effects of newer regimens in relapsed/refractory HER2+ metastatic breast cancer as well as advice for oncology nurses.

Videos

Management of Adverse Effects in R/R HER2+ mBC

Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management ofHER2+breast cancer and examining the potential use of at-home administration.

Data from the following clinical trial are discussed:

Patient preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab and trastuzumab in pts with HER2-positive early breast cancer: Interim analysis of the open-label, randomized crossover PHranceSCa study. (O’Shaughnessy J et al. 2020 ESMO annual meeting. Abstract 80O.)

HER2-targeted Therapy: Routes of Administration

Nurse practitioners provide insight on issues surrounding the administration of dual HER2-targeted therapy in the neoadjuvant/adjuvant setting and counseling patients on common AEs associated with trastuzumab-pertuzumab for the treatment of HER2+ breast cancer.

Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

Articles

Management of Adverse Effects in R/R HER2+ mBC

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

HER2-targeted Therapy: Routes of Administration

Practical Management of Early Stage HER2+ Breast Cancer